Cloud Joann L, Conville Patricia S, Croft Ann, Harmsen Dag, Witebsky Frank G, Carroll Karen C
ARUP Institute for Clinical and Experimental Pathology, Department of Pathology, University of Utah, Salt Lake City, Utah, USA.
J Clin Microbiol. 2004 Feb;42(2):578-84. doi: 10.1128/JCM.42.2.578-584.2004.
Identification of clinically significant nocardiae to the species level is important in patient diagnosis and treatment. A study was performed to evaluate Nocardia species identification obtained by partial 16S ribosomal DNA (rDNA) sequencing by the MicroSeq 500 system with an expanded database. The expanded portion of the database was developed from partial 5' 16S rDNA sequences derived from 28 reference strains (from the American Type Culture Collection and the Japanese Collection of Microorganisms). The expanded MicroSeq 500 system was compared to (i). conventional identification obtained from a combination of growth characteristics with biochemical and drug susceptibility tests; (ii). molecular techniques involving restriction enzyme analysis (REA) of portions of the 16S rRNA and 65-kDa heat shock protein genes; and (iii). when necessary, sequencing of a 999-bp fragment of the 16S rRNA gene. An unknown isolate was identified as a particular species if the sequence obtained by partial 16S rDNA sequencing by the expanded MicroSeq 500 system was 99.0% similar to that of the reference strain. Ninety-four nocardiae representing 10 separate species were isolated from patient specimens and examined by using the three different methods. Sequencing of partial 16S rDNA by the expanded MicroSeq 500 system resulted in only 72% agreement with conventional methods for species identification and 90% agreement with the alternative molecular methods. Molecular methods for identification of Nocardia species provide more accurate and rapid results than the conventional methods using biochemical and susceptibility testing. With an expanded database, the MicroSeq 500 system for partial 16S rDNA was able to correctly identify the human pathogens N. brasiliensis, N. cyriacigeorgica, N. farcinica, N. nova, N. otitidiscaviarum, and N. veterana.
在患者诊断和治疗中,将具有临床意义的诺卡菌鉴定到种水平很重要。进行了一项研究,以评估通过带有扩展数据库的MicroSeq 500系统对部分16S核糖体DNA(rDNA)进行测序来鉴定诺卡菌的情况。该数据库的扩展部分是根据来自28个参考菌株(来自美国典型培养物保藏中心和日本微生物保藏中心)的部分5' 16S rDNA序列开发的。将扩展的MicroSeq 500系统与以下方法进行比较:(i)结合生长特性以及生化和药敏试验获得的传统鉴定方法;(ii)涉及对16S rRNA和65 kDa热休克蛋白基因部分进行限制性内切酶分析(REA)的分子技术;(iii)必要时,对16S rRNA基因的999 bp片段进行测序。如果通过扩展的MicroSeq 500系统对部分16S rDNA进行测序获得的序列与参考菌株的序列相似度达到99.0%,则将未知分离株鉴定为特定物种。从患者标本中分离出代表10个不同物种的94株诺卡菌,并使用三种不同方法进行检测。通过扩展的MicroSeq 500系统对部分16S rDNA进行测序,在物种鉴定方面与传统方法的一致性仅为72%,与替代分子方法的一致性为90%。鉴定诺卡菌物种的分子方法比使用生化和药敏试验的传统方法提供更准确、快速的结果。通过扩展数据库,用于部分16S rDNA的MicroSeq 500系统能够正确鉴定人类病原体巴西诺卡菌、乔治亚那诺卡菌、豚鼠耳炎诺卡菌、新星诺卡菌、鼻窦诺卡菌和 veterana诺卡菌。